Last reviewed · How we verify
Digoxin Tablets
At a glance
| Generic name | Digoxin Tablets |
|---|---|
| Sponsor | Guangdong Raynovent Biotech Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults (PHASE1)
- Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (PHASE3)
- Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin (PHASE1)
- A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis (NA)
- Effect of Estrogen Treatment on Drug Metabolism and Transport (PHASE4)
- A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjects (PHASE1)
- Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection (PHASE1)
- Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Digoxin Tablets CI brief — competitive landscape report
- Digoxin Tablets updates RSS · CI watch RSS
- Guangdong Raynovent Biotech Co., Ltd portfolio CI